期刊
JACC-CARDIOVASCULAR INTERVENTIONS
卷 11, 期 14, 页码 1401-1410出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcin.2018.04.008
关键词
catheter-directed therapy; fibrinolysis; pulmonary embolism; right ventricular failure; thrombolysis
资金
- Ekos/BTG
- BiO2 Medical
- Bayer
- Daiichi-Sankyo
- Inari
- Janssen
- Portola
- Penumbra
- Angiodynamics
- Boston Scientific
- Medtronic
- Edwards Lifesciences
- St. Jude Medical
- Cordis
- Abbott
- Sirtex
- Merit Medical
- Zimmer Biomet
- Cook Medical
- BTG
- CSI
- Gore
- Bristol-Myers Squibb
OBJECTIVES The aim of this study was to determine the lowest optimal tissue plasminogen activator (tPA) dose and delivery duration using ultrasound-facilitated catheter-directed thrombolysis (USCDT) for the treatment of acute intermediate-risk (submassive) pulmonary embolism. BACKGROUND Previous trials of USCDT used tPA over 12 to 24 h at doses of 20 to 24 mg for acute pulmonary embolism. METHODS Hemodynamically stable adults with acute intermediate-risk pulmonary embolism documented by computed tomographic angiography were randomized into this prospective multicenter, parallel-group trial. Patients received treatment with 1 of 4 USCDT regimens. The tPA dose ranged from 4 to 12 mg per lung and infusion duration from 2 to 6 h. The primary efficacy endpoint was reduction in right ventricular-to-left ventricular diameter ratio by computed tomographic angiography. A major secondary endpoint was embolic burden by refined modified Miller score, measured on computed tomographic angiography 48 h after initiation of USCDT. RESULTS One hundred one patients were randomized, and improvements in right ventricular-to-left ventricular diameter ratio were as follows: arm 1 (4 mg/lung/2 h), 0.40 (24%; p = 0.0001); arm 2 (4 mg/lung/4 h), 0.35 (22.6%; p = 0.0001); arm3 (6 mg/lung/6 h), 0.42 (26.3%; p = 0.0001); and arm4 (12 mg/lung/6 h), 0.48 (25.5%; p = 0.0001). Improvement in refined modified Miller score was also seen in all groups. Four patients experienced major bleeding (4%). Of 2 intracranial hemorrhage events, 1 was attributed to tPA delivered by USCDT. CONCLUSIONS Treatment with USCDT using a shorter delivery duration and lower-dose tPA was associated with improved right ventricular function and reduced clot burden compared with baseline. The major bleeding rate was low, but 1 intracranial hemorrhage event due to tPA delivered by USCDT did occur. (c) 2018 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据